Evommune's pre-market share price fell 18.1%. Previously, the eczema drug developed by the company did not reach the main end of the mid-term trial.

Evommune's pre-market share price fell 18.1%. Previously, the eczema drug developed by the company did not reach the main end of the mid-term trial.